{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:34:22Z","timestamp":1761964462064,"version":"build-2065373602"},"reference-count":54,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T00:00:00Z","timestamp":1306800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet\/thrombotic inhibition, lipid\u2010 and blood pressure\u2010lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed\u2010dose combination drugs, laboratory screening for drug tailoring, and community\u2010based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.<\/jats:p>","DOI":"10.1111\/j.1755-5922.2011.00280.x","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T03:39:34Z","timestamp":1306899574000},"page":"257-263","source":"Crossref","is-referenced-by-count":15,"title":["Novel Treatments for Cardiovascular Disease Prevention"],"prefix":"10.1111","volume":"30","author":[{"given":"Mark D.","family":"Huffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"e_1_2_11_2_2","unstructured":"World Health Organization.Disease and injury regional estimates for 2004 Geneva Switzerland. Available from:http:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates_regional\/en\/index.html[Accessed 5 September2009."},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.154856"},{"key":"e_1_2_11_4_2","unstructured":"United States Food and Drug Administration.2006.FDA approves novel medication for smoking cessation. Available from:http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108651.htm[Accessed 10 June 2010."},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.869008"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1561"},{"key":"e_1_2_11_8_2","unstructured":"United Staes Food and Drug Administration.Postmarket drug safety information for healthcare professionals: Varenicline (marketed as Chantix). Available from:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm169986.htm[Accessed 10 June2010."},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0907122"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0806848"},{"key":"e_1_2_11_12_2","unstructured":"United States Food and Drug Administration.2010.Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting. Available from:http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM220197.pdf[Accessed 5 August 2010."},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908628"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908629"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685974"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.11.025"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.033"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.606442"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.069"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"e_1_2_11_23_2","first-page":"31","article-title":"Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin","volume":"5","author":"Robinson JG","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009744"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2830"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2875"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3048"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.03.011"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1870"},{"key":"e_1_2_11_30_2","unstructured":"United States Food and Drug Administration.2007.Drug approval package. Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021985s000TOC.cfm[Accessed 4 August 2010."},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2007.04.004"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.826214"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708379"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61343-X"},{"key":"e_1_2_11_36_2","unstructured":"United States Food and Drug Administration.2009.Circulatory system devices panel April 23 2009 meeting. Available from:http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/MedicalDevices\/MedicalDevicesAdvisoryCommittee\/CirculatorySystemDevicesPanel\/ucm152596.htm[Accessed 4 August 2010."},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308291101"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1419"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60611-5"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7499.1035"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068219"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1419"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.056"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.02.012"},{"key":"e_1_2_11_47_2","unstructured":"Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER\u2010PCI) design. Available from:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00910299[Accessed 5 August2010."},{"key":"e_1_2_11_48_2","unstructured":"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC). Available from:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00827411?term=ARCTIC&rank=1[Accessed 5 August2010."},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.831198"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_11_51_2","unstructured":"FDA Approves New Indication for Crestor. Available from:http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm200128.htm[Accessed 5 August2010."},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.189"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.2.201"},{"key":"e_1_2_11_54_2","first-page":"CD001561","article-title":"Multiple risk factor interventions for primary prevention of coronary heart disease","author":"Ebrahim S","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.062"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5922.2011.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5922.2011.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:33:00Z","timestamp":1698712380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5922.2011.00280.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1755-5922.2011.00280.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5922.2011.00280.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"type":"print","value":"1755-5914"},{"type":"electronic","value":"1755-5922"}],"subject":[],"published":{"date-parts":[[2011,5,31]]}}}